PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOmidenepag isopropyl
Omidenepag isopropyl
Omlonti (omidenepag isopropyl) is a small molecule pharmaceutical. Omidenepag isopropyl was first approved as Omlonti on 2022-09-22. It is used to treat intraocular pressure in the USA. It is known to target prostaglandin E2 receptor EP2 subtype.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
ocular physiological phenomenaD009799
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Omidenepag isopropyl
Tradename
Company
Number
Date
Products
OMLONTISantenN-215092 DISCN2022-09-22
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
omlontiNew Drug Application2023-10-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
intraocular pressure—D007429—
Agency Specific
FDA
EMA
Expiration
Code
OMIDENEPAG ISOPROPYL, OMLONTI, SANTEN
2027-09-22NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Omidenepag Isopropyl, Omlonti, Santen
116665632039-07-16U-3454
107740722035-06-10DP
RE481832035-01-08DPU-3454
94150382035-01-08DPU-3454
101791272035-01-08DPU-3454
107025112035-01-08DPU-3454
107657502035-01-08DP
111978492035-01-08DPU-3454
86480972029-10-13DS, DP
86859862029-10-13DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101571—12
Ocular hypertensionD009798EFO_1001069H40.01571—12
GlaucomaD005901EFO_0000516H401571—12
Open-angle glaucomaD005902EFO_0004190H40.1—451—9
Low tension glaucomaD057066EFO_1001022H40.12———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOmidenepag isopropyl
INN—
Description
Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.
Classification
Small molecule
Drug classnon-prostanoid prostaglandin receptor agonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1
Identifiers
PDB—
CAS-ID1187451-19-9
RxCUI—
ChEMBL IDCHEMBL4297666
ChEBI ID—
PubChem CID44230999
DrugBankDB15071
UNII ID—
Target
Agency Approved
No data
Alternate
PTGER2
PTGER2
Organism
Homo sapiens
Gene name
PTGER2
Gene synonyms
NCBI Gene ID
5732
Protein name
prostaglandin E2 receptor EP2 subtype
Protein synonyms
PGE receptor EP2 subtype, PGE2 receptor EP2 subtype, prostaglandin E receptor 2 (subtype EP2), 53kD, prostaglandin E receptor 2 (subtype EP2), 53kDa, Prostanoid EP2 receptor
Uniprot ID
Q52LG8
Mouse ortholog
Ptger2 (19217)
prostaglandin E2 receptor EP2 subtype (Q62053)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 107 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
13 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use